FCCC LOGO Faculty Publications
Qiu CC , Kotredes KP , Cremers T , Patel S , Afanassiev A , Slifker M , Gallucci S , Gamero AM
Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production
Oncoimmunology. 2020 Dec 29;10(1) :1860477
PMID: 33457079    PMCID: PMC7781843    URL: https://www.ncbi.nlm.nih.gov/pubmed/33457079
Back to previous list
Abstract
STAT2 is a central component of the ISGF3 transcriptional complex downstream of type I interferon (IFN-I) signaling. The significance of in vivo IFN-I/STAT1 signals in cDCs is well-established in the generation of antitumor cytotoxic T cell (CTL) responses. However, the role of STAT2 has remained elusive. Here, we report a clinical correlation between cDC markers and STAT2 associated with better survival in human metastatic melanoma. In a murine tumor transplantation model, targeted Stat2 deletion in CD11c+cDCs enhanced tumor growth unaffected by IFNβ therapy. Furthermore, STAT2 was essential for both, the activation of CD8a+cDCs and CD11b+cDCs and antigen cross-presentation in vivo for the generation of robust T cell killing response. In contrast, STAT2 in CD11c+cDCs was dispensable for stimulating an antigen-specific humoral response, which was impaired in global Stat2 deficient mice. Thus, our studies indicate that STAT2 in cDCs is critical in host IFN-I signals by sculpting CTL responses against tumors.
Notes
2162-402x Qiu, Connie C Kotredes, Kevin P Cremers, Tess Patel, Sajan Afanassiev, Alexandra Slifker, Michael Gallucci, Stefania Gamero, Ana M Orcid: 0000-0001-7843-1415 Journal Article Oncoimmunology. 2020 Dec 29;10(1):1860477. doi: 10.1080/2162402X.2020.1860477.